Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

Inclusion Criteria: * Must be 18 years or older * Must have a performance status of at least 70% (able to carry on most normal activities) * Must have life expectancy of at least 3 months * Must have adequate organ and marrow function as determined by lab tests * Women of child-bearing potential and men must agree to use two forms of contraception * Ability and willingness to sign a written informed consent document * Histologically confirmed solid tumor malignancy that is metastatic or unresectable Exclusion Criteria: * Pregnant or breastfeeding and/or lactating women * Patients who have received any other investigational agents within 28 days of the first day of study drug * Patients with known CNS metastases * History of other carcinomas within last 5 years (except non-melanoma skin cancer, in-situ cervical cancer, localized prostate cancer) * Inadequately controlled hypertension * Significant vascular disease * Invasion or encasement of a major artery * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 of study drug * Serious illness or medical condition * History of myocardial infarction, unstable angina, cardiac or other vascular stenting * History of stroke * HIV, Hepatitis C, Hepatitis B or other serious chronic infection * Impairment of Gastrointestinal function or disease * History of interstitial lung disease * Patients who have had radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer within 28 days of receiving study drug.